OpenLegislation

Division b) ContentF1

United Kingdom

Original text. Later amendments are not shown.

The Vaccine Antigen Master File shall contain the following information extracted from the relevant part (Active substance) of Module 3 on ‘ Quality Data ’ as delineated in Part I of this Annex:

  • Active Substance

    1. 1..

      General Information, including compliance with the relevant monograph(s) of the European Pharmacopoeia.

    2. 2..

      Information on the manufacture of the active substance: this heading must cover the manufacturing process, information on the starting and raw materials, specific measures on TSEs and adventitious agents safety evaluation and facilities and equipment.

    3. 3..

      Characterisation of the active substance

    4. 4..

      Quality control of the active substance

    5. 5..

      Reference standard and materials

    6. 6..

      Container and closure system of the active substance

    7. 7..

      Stability of the active substance.

Annotations

Textual amendments

F1

Substituted by Commission directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance).